MedTrace Logo

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

NCT05594797 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-12-09

No results posted yet for this study

Summary

A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection（BCMA CAR-T） Therapy for R/R MM.

Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of BCMA CAR+ T cells.

Conditions

Interventions

DRUG

Human BCMA Targeted T Cells Injection

A single dose of predetermined level CAR-positive T cells will be infused.

Sponsors & Collaborators

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • Hrain Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Juan Du, Ph.D. · Shanghai Changzheng Hospital

  • Songfu Jiang, Professor · First Affiliated Hospital of Wenzhou Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-12
Primary Completion
2025-07-31
Completion
2027-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05594797 on ClinicalTrials.gov